We are live on ! Find out more
PCVX icon

Vaxcyte
PCVX

251 hedge funds and large institutions have $8.13B invested in Vaxcyte in 2024 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 102 increasing their positions, 77 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 18

37% more call options, than puts

Call options by funds: $16.7M | Put options by funds: $12.2M

32% more repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 77

25% more capital invested

Capital invested by funds: $6.51B → $8.13B (+$1.63B)

13% more funds holding

Funds holding: 223 → 251 (+28)

0.97% more ownership

Funds ownership: 108.91% → 109.87% (+0.97%)

14% less funds holding in top 10

Funds holding in top 10: 14 → 12 (-2)

Holders
251
Holders Change
+28
Holders Change %
+12.56%
% of All Funds
3.62%
Holding in Top 10
12
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-14.29%
% of All Funds
0.17%
New
48
Increased
102
Reduced
77
Closed
18
Calls
$16.7M
Puts
$12.2M
Net Calls
+$4.53M
Net Calls Change
-$2.42M

Top Buyers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$160M
2
DGM
Darwin Global Management
Jersey
+$150M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$142M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$89M
5
PBA
Paradigm Biocapital Advisors
New York
+$85.9M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$40.5M
2
Millennium Management
Millennium Management
New York
-$33.5M
3
VPC
Vestal Point Capital
New York
-$33M
4
GPP
Great Point Partners
Connecticut
-$22.6M
5
Pictet Asset Management
Pictet Asset Management
Switzerland
-$19.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Norges Bank
26
Norges Bank
Norway
$71.5M +$9.04M +130,520 +14%
Northern Trust
27
Northern Trust
Illinois
$66.2M +$5.85M +84,489 +10%
Pictet Asset Management
28
Pictet Asset Management
Switzerland
$58.9M -$19.9M -287,640 -25%
CC
29
Commodore Capital
New York
$58.7M -$16.6M -240,000 -22%
NHAS
30
Novo Holdings A/S
Denmark
$57.7M – – –
Charles Schwab
31
Charles Schwab
California
$56.9M +$7.14M +103,180 +14%
PBPIA
32
Pivotal bioVenture Partners Investment Advisor
California
$54.2M – – –
KCM
33
Kynam Capital Management
New Jersey
$50.9M -$17.8M -257,407 -26%
Goldman Sachs
34
Goldman Sachs
New York
$47.7M +$15.1M +217,373 +45%
CAM
35
Cormorant Asset Management
Massachusetts
$46.8M +$1.38M +20,000 +3%
EAM
36
Eventide Asset Management
Massachusetts
$44.9M +$3.46M +50,000 +8%
ACA
37
Avoro Capital Advisors
New York
$39.3M +$39.8M +575,000 New
Morgan Stanley
38
Morgan Stanley
New York
$33.5M -$40.5M -584,276 -54%
Ensign Peak Advisors
39
Ensign Peak Advisors
Utah
$32.5M +$7.93M +114,569 +32%
American Century Companies
40
American Century Companies
Missouri
$31.5M +$3.77M +54,495 +13%
Federated Hermes
41
Federated Hermes
Pennsylvania
$29.1M +$2.19M +31,558 +8%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$28.2M +$928K +13,408 +3%
WP
43
Woodline Partners
California
$26.9M +$24.4K +353 +0.1%
Lord, Abbett & Co
44
Lord, Abbett & Co
New Jersey
$26.3M -$83.9K -1,211 -0.3%
FCM
45
Farallon Capital Management
California
$25.8M +$25.9M +374,000 +11,000%
D.E. Shaw & Co
46
D.E. Shaw & Co
New York
$25.1M -$4.92M -71,062 -16%
MC
47
Maverick Capital
Texas
$24.3M +$24.6M +355,131 New
EAM
48
Eagle Asset Management
Florida
$22.6M -$1.06M -15,323 -4%
N
49
Nuveen
North Carolina
$21.3M +$2.11M +30,496 +11%
SC
50
Samlyn Capital
New York
$20.7M -$1.84M -26,530 -8%
1
2
3 4 5

PCVX Hedge Fund Activity: Q1 2024 in Review

251 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q1 2024, worth a combined $8.13B — up 25% from $6.51B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new PCVX positions and 18 closed out — a net gain of 30 holders — while 102 added to existing stakes and 77 trimmed.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $160M. The largest seller was Morgan Stanley, cutting an estimated $40.5M.

  • 251 institutional investors held Vaxcyte (PCVX) as of Q1 2024, up from 223 in Q4 2023.
  • Funds reported $8.13B of Vaxcyte stock for Q1 2024, up 25% quarter-over-quarter.
  • 48 funds opened new Vaxcyte positions in Q1 2024 and 18 closed out, a net change of +30 holders.
  • The largest Vaxcyte buyer in Q1 2024 was T. Rowe Price Investment Management, an estimated $160M added.
  • The largest Vaxcyte seller in Q1 2024 was Morgan Stanley, an estimated $40.5M sold.

Based on aggregated 13F filings for Q1 2024.